Pharma and Biotech Sector Signals Strategic Pivot Toward Profitable Scaling
The final quarter of 2025 revealed a sector-wide shift toward operational discipline and high-margin product expansion among leading biotech and pharma entities. Key players like Indivior and Pacira reported significant volume growth in flagship therapies while successfully navigating patent challenges and portfolio optimizations.